Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“We are continuing to demonstrate our leadership in genitourinary cancers at ESMO25 as we unveil pivotal Phase 3 data in Bladder Cancer. For decades, people with cisplatin-ineligible muscle-invasive bladder cancer have faced limited treatment options and a poor prognosis. Today, with our partners Astellas Pharma and Merck, we’re sharing unprecedented event-free and overall survival data:
These results have the potential to change the standard of care and make a meaningful impact for patients and their families.
My deepest thanks to the trial participants and investigators for participation in this important research.”
Proceed to the video attached to the post.
You can also read: ESMO 2025 Day 2 Highlights Not to Miss
